20 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
and Cas12a chRDNA technologies. Our Team Our team and our culture are critical to our mission to develop innovative, transformative therapies for patients … Components of our Strategy Our mission is to develop innovative, transformative therapies for patients with devastating diseases through our novel chRDNA
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
11 Mar 24
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:22pm
to inform two clinical datasets this year as part of our mission of bringing transformative therapies to patients with devastating diseases
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
and strategic vision, will be instrumental as we advance our pipeline and plan for the future. We are pleased to have Tim join us on our mission
8-K
EX-99.2
CRBU
Caribou Biosciences Inc
13 Jul 23
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
4:23pm
Hospital, Columbus Additional sites coming soon THANK YOU for your contributions toward Caribou’s mission to develop innovative, transformative therapies … toward Caribou’s mission to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing
24 CB-010
ARS
thktrxhdmjf05 1uq82s
28 Apr 23
Annual report to shareholders
12:00am
DEFA14A
0plfrieoxeqd3785wmr8
11 Aug 22
Additional proxy soliciting materials
4:06pm
8-K
EX-99.2
v9gh0p8c58a
10 Jun 22
Regulation FD Disclosure
7:54am
8-K
EX-99.2
v15x2zyi75w xtf
12 May 22
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19
10:03am
10-K
dhdnkjx54zbpdj9v
21 Mar 22
Annual report
4:19pm
8-K
EX-99.1
i7err 6gftub70qqa
18 Jan 22
Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer
8:02am
424B4
gem5wm5 1dlr
23 Jul 21
Prospectus supplement with pricing info
4:24pm
S-1/A
8f8hom7q un10p
19 Jul 21
IPO registration (amended)
6:09am
S-1
z0fq3
1 Jul 21
IPO registration
4:05pm
S-1
EX-10.1
b17p8ewnfnp
1 Jul 21
IPO registration
4:05pm
DRS/A
EX-10.1
wl5g 8fkqu96o5wosja
11 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
c5mccb
11 Jun 21
Draft registration statement (amended)
12:00am
DRS
EX-10.1
ts8jf5e82ylzx
7 May 21
Draft registration statement
12:00am
DRS
mtk eh27cv
7 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next